Sionna Therapeutics, INC Form 4 insider transactions

Laurie Stelzer, a Director at Sionna Therapeutics, Inc., was granted 19,959 non-qualified stock options with an exercise price of $16.99, vesting upon the earlier of June 12, 2026, or the next annual meeting.

Sionna Therapeutics, Inc. director Marcella K. Ruddy was granted non-qualified stock options to purchase 19,959 shares of common stock at an exercise price of $16.99 per share, with vesting tied to continued service.

Sionna Therapeutics, Inc. Director Joshua Resnick was granted 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.

Sionna Therapeutics Director Harold Edward Fleming acquired 19,959 non-qualified stock options with an exercise price of $16.99, though he disclaims beneficial ownership as they are held for Enavate Sciences, LP.

Sionna Therapeutics, Inc. Director Paul J. Clancy was granted 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.

Sionna Therapeutics, Inc. Director Bruce Booth has reported the grant of 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, reported changes in beneficial ownership of Sionna Therapeutics common stock following the company's initial public offering on February 10, 2025.

RA Capital Management and related entities report changes in beneficial ownership of Sionna Therapeutics common stock following the conversion of preferred stock in connection with the company's initial public offering.

OrbiMed Advisors and related entities disclose ownership stake in Sionna Therapeutics following the company's initial public offering.

Director Marcella K. Ruddy acquired stock options in Sionna Therapeutics, signaling potential future ownership.

Director Joanne L. Viney of Sionna Therapeutics acquired stock options for 39,919 shares of common stock on February 6, 2025.

Michael Cloonan, President & CEO of Sionna Therapeutics, was granted stock options to purchase 450,252 shares of common stock on February 6, 2025.

Elena Ridloff, CFO & Head of Corporate Development at Sionna Therapeutics, was granted stock options for 157,820 shares on February 6, 2025.

Following Sionna Therapeutics' initial public offering, director Peter A. Thompson reports changes in beneficial ownership of common stock due to conversion of preferred stock and open market purchases.

Director Bruce Booth reports the conversion of preferred stock to common stock and purchases of common stock following Sionna Therapeutics' initial public offering.

Atlas Venture Funds report changes in beneficial ownership of Sionna Therapeutics common stock following the company's initial public offering.

Charlotte McKee, Chief Medical Officer of Sionna Therapeutics, acquired stock options for 148,536 shares of common stock on February 6, 2025.